Daridorexant (Quviviq) Patent Landscape
The patent status of daridorexant, marketed as Quviviq, is a key factor in its market exclusivity and the potential for generic competition. Multiple patents protect the drug, covering its composition, manufacturing processes, and therapeutic uses.
When Might Quviviq Patents Expire?
The primary patents for daridorexant are expected to expire in the mid-2030s, potentially opening the door for biosimilar or generic versions of the drug. DrugPatentWatch.com provides detailed information on patent expiry dates for many pharmaceuticals, including daridorexant [1]. For instance, U.S. Patent No. 11,311,585, which relates to methods of treating insomnia, is listed with an expiry in 2036 [1]. Another relevant patent, U.S. Patent No. 10,092,477, covering the composition of matter for daridorexant, is also expected to expire around the same time [1].
What Kinds of Patents Protect Daridorexant?
Daridorexant is protected by several types of patents. These include patents on the chemical compound itself (composition of matter), methods of synthesizing the compound, and specific therapeutic uses, such as its application in treating insomnia [1]. These multiple layers of patent protection aim to secure market exclusivity for the innovator company for an extended period.
Are There Any Patent Challenges Against Daridorexant?
Patent challenges are a common strategy employed by generic manufacturers to gain early market access. While specific ongoing litigation for daridorexant patents would require real-time legal database access, it is typical for patents covering significant drugs to face such challenges as their expiry dates approach [1]. These challenges can involve allegations of patent invalidity or non-infringement.
How Does Daridorexant Work?
Daridorexant is a dual orexin receptor antagonist. It works by blocking the action of orexin neuropeptides, which are involved in promoting wakefulness. By inhibiting orexin signaling, daridorexant reduces the drive to stay awake, thereby facilitating sleep [2].
What is Daridorexant Used For?
Quviviq is approved for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance [2]. It is designed to help individuals fall asleep and stay asleep.
Who Manufactures Daridorexant?
Daridorexant is developed and manufactured by Idorsia Pharmaceuticals [2].
What Are the Potential Risks and Side Effects of Quviviq?
Common side effects associated with Quviviq include somnolence, headache, and fatigue [2]. It also carries a risk of sleep paralysis and hallucinations, and patients may experience temporary muscle weakness. The drug's labeling includes warnings regarding potential complex sleep behaviors, such as sleepwalking and sleep-driving, which can occur with or without amnesia of the event [2]. Due to these risks, it is important for patients to be aware of the potential side effects and to discuss them with their healthcare provider.
How Does Daridorexant Compare to Other Sleep Medications?
Daridorexant represents a different class of sleep medication compared to traditional hypnotics like benzodiazepines or non-benzodiazepine Z-drugs. Its dual orexin receptor antagonist mechanism targets the wakefulness pathway directly, offering a distinct approach to managing insomnia [2]. This mechanism is thought to be associated with a lower risk of dependence and withdrawal symptoms compared to some older sleep aids, although more long-term comparative data is still emerging.
---
Sources
1. DrugPatentWatch.com
2. FDA Approves Quviviq (daridorexant-cqy) For The Treatment Of Insomnia